美國研究人員9月15日說，血液中3種蛋白質(zhì)可以“提早”顯現(xiàn)肺癌,，比癌癥癥狀顯露時間早大約一年,。
美國弗雷德·哈欽森癌癥研究中心研究人員在一年時間里，檢驗了170名吸煙或曾經(jīng)吸煙者的血液樣本,，其中85人被診斷患有癌癥,，85人沒有患癌癥。
結(jié)果發(fā)現(xiàn),，患有癌癥的測試對象中,，51%的人血液中含有annexin1、14—3—3θ和LAMR1三種蛋白質(zhì),。
研究中心教授米爾·哈奈什說：“這是關(guān)鍵的一步,，這說明，實際上,，某些抗原確實在診斷出肺癌前就開始活躍,。這時，主體還沒有任何癥狀,。”
哈奈什說,，5年內(nèi)有望開發(fā)出血液檢測肺癌的方法。
“患癌癥過程中,，免疫系統(tǒng)識別出腫瘤抗原這種外來蛋白質(zhì),，”哈奈什說，“免疫系統(tǒng)認(rèn)為這些是異常蛋白質(zhì),，會對它們作出反應(yīng),。”
研究結(jié)果發(fā)表在最新一期《臨床腫瘤學(xué)雜志》（Journal of Clinical Oncology）上。（生物谷Bioon.com）
生物谷推薦原始出處：
Journal of Clinical Oncology,，10.1200/JCO.2008.16.2388,，Ji Qiu,，Samir M. Hanash
Occurrence of Autoantibodies to Annexin I, 14-3-3 Theta and LAMR1 in Prediagnostic Lung Cancer Sera
Ji Qiu,* Gina Choi, Lin Li, Hong Wang, Sharon J. Pitteri, Sandra R. Pereira-Faca, Alexei L. Krasnoselsky, Timothy W. Randolph, Gilbert S. Omenn, Cim Edelstein, Matt J. Barnett, Mark D. Thornquist, Gary E. Goodman, Dean E. Brenner, Ziding Feng, and Samir M. Hanash
Purpose: We have implemented a high throughput platform for quantitative analysis of serum autoantibodies, which we have applied to lung cancer for discovery of novel antigens and for validation in prediagnostic sera of autoantibodies to antigens previously defined based on analysis of sera collected at the time of diagnosis.
Materials and Methods: Proteins from human lung adenocarcinoma cell line A549 lysates were subjected to extensive fractionation. The resulting 1,824 fractions were spotted in duplicate on nitrocellulose-coated slides. The microarrays produced were used in a blinded validation study to determine whether annexin I, PGP9.5, and 14-3-3 theta antigens previously found to be targets of autoantibodies in newly diagnosed patients with lung cancer are associated with autoantibodies in sera collected at the presymptomatic stage and to determine whether additional antigens may be identified in prediagnostic sera. Individual sera collected from 85 patients within 1 year before a diagnosis of lung cancer and 85 matched controls from the Carotene and Retinol Efficacy Trial (CARET) cohort were hybridized to individual microarrays.
Results: We present evidence for the occurrence in lung cancer sera of autoantibodies to annexin I, 14-3-3 theta, and a novel lung cancer antigen, LAMR1, which precede onset of symptoms and diagnosis.
Conclusion: Our findings suggest potential utility of an approach to diagnosisof lung cancer before onset of symptoms that includes screening for autoantibodies to defined antigens.
